Spyre Therapeutics (SYRE) Price & Analysis

Compare

478 Followers

SYRE Stock Chart & Stats

$29.75

-$0.27(-1.11%)

At close: Jan 08 4:00 PM EST

$29.75

-$0.27(-1.11%)

Day’s Range― - ―

52-Week Range$10.91 - $29.78

Previous CloseN/A

Volume84.75K

Average Volume (3M)798.94K

Market Cap

$2.31B

Enterprise Value$532.42M

Total Cash (Recent Filing)$486.20M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.54

Next Earnings

Feb 26, 2026

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding77,592,130

10 Day Avg. Volume608,315

30 Day Avg. Volume798,943

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)2.11

Price to Sales (P/S)0.00

P/FCF Ratio-6.96

Enterprise Value/Market Cap0.23

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-11.77

Enterprise Value/Ebitda-2.99

Forecast

1Y Price Target

$54.00

Price Target Upside81.51% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-2.18

Revenue Forecast (FY)$88.60K

Bulls Say, Bears Say

Bulls Say

Financial PositionSYRE ended with pro forma cash and equivalents of $782.7M, which the company is guiding as sufficient to fund operations into the second half of 2028.

Innovative Platform DesignThe trial utilizes an innovative platform design that enables new cohorts to be added over time.

Phase II ReadoutsSpyre expects six Phase II readouts from SKYLINE-UC (IBD) and SKYWAY-RD (rheum) in 2026, which could generate significant value for investors.

Bears Say

Drug Trial FailureThe drug MORF-057 has failed in its subsequent placebo-controlled Ph2b EMERALD-2 UC trial.

Investor SkepticismShort Interest (% Float) is 18.8%.

Short InterestShort interest in Spyre's stock is relatively high, indicating some level of skepticism among investors.

Spyre Therapeutics News

Spyre Therapeutics reports Q3 EPS (15c), consensus (74c)

As of September 30, Spyre had cash, cash equivalents, and marketable securities of $486.2M. “We have now reported...

25d ago

SYRE

Spyre Therapeutics: Promising Innovations and Strong Financials Justify Buy Rating

Analyst Julian Harrison of BTIG maintained a Buy rating on Spyre Therapeutics, retaining the price target of $70.00....

24d ago

SYRE

Spyre Therapeutics Reports Q3 2025 Financial Results

Spyre Therapeutics, Inc ( ($SYRE) ) has released its Q3 earnings. Here is a breakdown of the information...

25d ago

SYRE

Spyre Therapeutics Reports Positive Phase 1 Results for SPY003

An announcement from Spyre Therapeutics ( ($SYRE) ) is now available. On November 4, 2025, Spyre Therapeutics announced...

25d ago

SYRE

Spyre Therapeutics Advances in Ulcerative Colitis Treatment Study

Spyre Therapeutics, Inc (($SYRE)) announced an update on their ongoing clinical study. Spyre Therapeutics, Inc. is conducting a...

1M ago

SYRE

Spyre Therapeutics Advances Phase 2 Study of SPY072 for Rheumatic Diseases

Spyre Therapeutics, Inc (($SYRE)) announced an update on their ongoing clinical study. Spyre Therapeutics, Inc. is conducting a...

1M ago

SYRE

Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development

Spyre Therapeutics, Inc (($SYRE)) announced an update on their ongoing clinical study. Spyre Therapeutics, Inc. is conducting a...

1M ago

SYRE

Spyre Therapeutics Advances with Phase 1 Study of SPY003-207

Spyre Therapeutics, Inc (($SYRE)) announced an update on their ongoing clinical study. Spyre Therapeutics, Inc. is conducting a...

1M ago

SYRE

Spyre Therapeutics Advances with Phase 1 Study of SPY002-072

Spyre Therapeutics, Inc (($SYRE)) announced an update on their ongoing clinical study. Spyre Therapeutics, Inc. (SYRE) is conducting...

1M ago

SYRE

Spyre Therapeutics Announces Public Stock Offering

Spyre Therapeutics ( ($SYRE) ) has provided an announcement. On October 13, 2025, Spyre Therapeutics entered into an...

1M ago

SYRE

Spyre Therapeutics 14.86M share Spot Secondary priced at $18.50

The deal priced at below last closing price of $18.92. Jefferies, TD Securities, Leerink, Stifel and Wedbush are...

2M ago

SYRE

Spyre Therapeutics announces common stock offering, no amount given

Spyre Therapeutics (SYRE) announced that it has commenced an underwritten public offering of shares of its common stock...

2M ago

SYRE

Spyre Therapeutics announces poster presentations at UEGW 2025

Spyre Therapeutics (SYRE) announced scientific presentations at the European Gastroenterology Week, UEGW, Congress. “We are excited to share...

2M ago

SYRE

Spyre Therapeutics initiated with a Buy at Deutsche Bank

Deutsche Bank initiated coverage of Spyre Therapeutics (SYRE) with a Buy rating and $43 price target The company’s...

2M ago

SYRE

SYRE FAQ

What was Spyre Therapeutics’s price range in the past 12 months?

Spyre Therapeutics lowest stock price was $10.91 and its highest was $29.78 in the past 12 months.

What is Spyre Therapeutics’s market cap?

Spyre Therapeutics’s market cap is $2.31B.

When is Spyre Therapeutics’s upcoming earnings report date?

Spyre Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 89 days.

How were Spyre Therapeutics’s earnings last quarter?

Spyre Therapeutics released its earnings results on Nov 04, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.761 by $0.611.

Is Spyre Therapeutics overvalued?

According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Spyre Therapeutics pay dividends?

Spyre Therapeutics does not currently pay dividends.

What is Spyre Therapeutics’s EPS estimate?

Spyre Therapeutics’s EPS estimate is -0.7.

How many shares outstanding does Spyre Therapeutics have?

Spyre Therapeutics has 77,592,130 shares outstanding.

What happened to Spyre Therapeutics’s price movement after its last earnings report?

Spyre Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.761. Following the earnings report the stock price went down -0.566%.

Which hedge fund is a major shareholder of Spyre Therapeutics?

Currently, no hedge funds are holding shares in SYRE

Spyre Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-32.63%

Trailing 12-Months

Asset Growth

19.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Spyre Therapeutics

Spyre Therapeutics (SYRE) is a biotechnology company focused on developing innovative treatments for autoimmune diseases. Leveraging cutting-edge research and advanced therapeutic platforms, Spyre Therapeutics aims to address the unmet medical needs in this sector. The company's core products include novel biologics and small molecule drugs designed to modulate the immune system effectively, providing patients with improved outcomes and quality of life.

Spyre Therapeutics (SYRE) Earnings & Revenues

Historic Earnings Reports

SYRE Stock 12 Month Forecast

Average Price Target

$54.00

▲(81.51% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","42":"$42","71":"$71","27.5":"$27.5","56.5":"$56.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$43.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,27.5,42,56.5,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.46,27.963076923076922,31.466153846153848,34.96923076923077,38.472307692307695,41.97538461538461,45.47846153846154,48.98153846153846,52.48461538461538,55.987692307692306,59.49076923076923,62.99384615384616,66.49692307692308,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.46,26.732307692307693,29.004615384615384,31.276923076923076,33.54923076923077,35.82153846153846,38.09384615384616,40.36615384615385,42.63846153846154,44.91076923076923,47.183076923076925,49.45538461538462,51.72769230769231,{"y":54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.46,25.886153846153846,27.312307692307694,28.73846153846154,30.164615384615384,31.590769230769233,33.01692307692308,34.44307692307692,35.86923076923077,37.29538461538462,38.72153846153846,40.14769230769231,41.573846153846155,{"y":43,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.46,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >